The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Lol...I'm expecting more than an interview on positive efficacy data, that was the last thing on my mind regardless of how lovely Miss Pilbeam's might be....Gl ;-)
Expecting a new interview once the 100 patients efficacy results are out ...
Wait and see
It the same one!!! :-)
This is most recent Proactive Investor interview to date.
Evgen Pharma CEO , Huw Jones, interviewed by Proactive Investors - 26th January 2021
https://www.youtube.com/watch?v=xwflrBd83kg&feature=youtu.be
This one should work On target, it was released shortly after the SHP2 Rns....Gl ;-)
https://youtu.be/xwflrBd83kg
I get 'video unavailable' on that link Moneymunch.. was it a new one?
Huw's interview, he talks about the potential of SHP2 over multiple cancer targets and "a very rare developmental disorder in children" and are now in the process of figuring out which disease to target as the one with the highest unmet medical need.
News expected in the coming weeks on whether or not this is related to the IND application in the US . Gla :-)
https://youtu.be/xwflrBd83k
sfx01 sounds a bit too good to be true ... almost like CBD did once ... but, that seems to have turned out quite well!
Bear in mind those words are the broker's jimbren, not the company's. I suspect it could be worded better e.g.
"An IND will be filed for the most suitable application after a thorough assessment process."
Lol....i think they have every clue, and not long before we find out, could be related to to SHP2 where Huw stated in a recent interview that they were still deciding on the specific cancer target for SHP2, or potentially it could be related to the University of Rocherster in New York, where SFX-01 has been under evaluation for Chronic Kidney Disease. Gl ;-)
Use of Proceeds
The Fundraising will raise gross proceeds of up to GBP11 million - admission date 4th March 2021
The net proceeds of the Fundraising are intended to be used as follows:
to fund further preclinical work for metastatic breast cancer (mBC), glioma and a further cancer indication yet to be announced;
subject to further pre-clinical progress, potentially fund a clinical trial in glioma patients;
to complete the formulation and scale up manufacturing of SFX-01;
to complete all preparatory work required to file an Investigational New Drug application in the US in respect of SFX-01; and
to fund the Group's operations through to mid-2023 including two key senior hires, being a Chief Business Officer and a Chief Scientific and Medical Officer.
.............
Solid tumour oncology target
In a collaboration which will be disclosed when patent filings and a scientific paper have been prepared, strong preclinical data has been generated when SFX-01 was evaluated in a model of a cancer with very poor life expectancy, and for which current treatments are limited.
In particular, in vitro studies with patient-derived cell lines showed dose-dependent reduction in proliferation and migration. Further, in vivo orthotopic xenograft models, treatment with SFX-01 increased disease-free survival and lengthened tumour progression times, an effect that is synergistic with radiotherapy.
Further preclinical work will be initiated shortly to complete the data set required for a clinical trial application and/or partnering discussions. The preclinical work should be completed by the middle of 2021 and a phase Ib/II could commence in Q1 of 2022.
Blood cancer target
Professor Philip Eaton at Queen Mary University of London has shown that SFX-01 inhibits activity of the non-receptor phosphotyrosine phosphatase, SHP2 (coded by the ptpn11 gene). SHP2 is thought to be a significant factor in some cancers and we have recently agreed to support work in well-renowned university to investigate whether SFX-01 has potential in a specific blood cancer disease.
“medical indication for the drug hasn’t been decided.”
I do own this one, but is this normal? Sounds more like “sorry, I haven’t a clue”.
Multiple newsflow expected from Huw across the pipeline, including Prof Chalmers preliminary efficacy assessment for Covid/ARDS, where positive data will be a complete game changer for all invested, and news on the IND could also be close which could be very well received. Momentum and excitement building in anticipation. Gla ;-)
SIGNIFICANT LANDMARK
An ambition (and a potential significant landmark/catalyst for the business) will be the filing of an investigational new drug application (IND) in the US for SFX-01, though medical indication for the drug hasn’t been decided.
This will start to motor on now.
08-Apr-2118:57:118.505,497,762Unknown*467.31k